publication_id	publication_abstract	publication_title	publication_author_all	publication_journal_short	publication_date	publication_volume	publication_issue	publication_location	publication_pmid	publication_link	publication_label	publication_author_first
1		Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques	"Sixsmith JD, Panas MW, Lee S, Gillard GO, White K, Lifton MA, Balachandran H, Mach L, Miller JP, Lavine C, DeMarco CT, Tomaras GD, Gee C, Porcelli SA, Larsen MH, Frothingham R, Schmitz JE, Jacobs WR, Haynes BF, Letvin NL, Korioth-Schmitz B"	Clin Vaccine Immunol	2014 Oct	21	10	1385-95	25080550	http://www.ncbi.nlm.nih.gov/pubmed/25080550	Sixsmith JD 2014 Clin Vaccine Immunol	Sixsmith JD
2		Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity	"Korioth-Schmitz B, Perley CC, Sixsmith JD, Click EM, Letvin NL, Frothingham R"	Vaccine	2015 Oct 13	33	42	5715-22	26192357	http://www.ncbi.nlm.nih.gov/pubmed/26192357	Korioth-Schmitz B 2015 Vaccine	Korioth-Schmitz B
3		Systemic vaccination induces clonally diverse SIV-specific CD8+ T-cell populations in systemic and mucosal compartments	"Sircar P, Furr KL, Letvin NL"	Mucosal Immunol	2013 Jan	6	1	93-103	22763409	http://www.ncbi.nlm.nih.gov/pubmed/22763409	Sircar P 2013 Mucosal Immunol	Sircar P
4		Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses	"Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL"	J Virol	2009 Jun	83	11	5505-13	19297477	http://www.ncbi.nlm.nih.gov/pubmed/19297477	Cayabyab MJ 2009 J Virol	Cayabyab MJ
5		Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates	"Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H, Pal R, Kwa S, Ding S, Yang OO, Fouda GG, Le Grande L, Bolton D, Esteban M, Phogat S, Roederer M, Amara R, Picker LJ, Seder RA, McElrath MJ, Barnett S, Permar SR, Shattock R, DeVico AL, Felber BK, Pavlakis GN, Pantaleo G, Korber BT, Montefiori DC, Tomaras GD"	J Virol	2015 Aug	89	16	8643-50	26018159	http://www.ncbi.nlm.nih.gov/pubmed/26018159	Shen X 2015 J Virol	Shen X
6		"Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo elctroporation"	"Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, Rosenberg TJ, Hannaman D, Vasan S"	Vaccine	2011 Jan 17	29	4	795-803	21094270	http://www.ncbi.nlm.nih.gov/pubmed/21094270	Dolter KE 2011 Vaccine	Dolter KE
7		Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens	"Asbach B, Kliche A, K�stler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R"	J Virol	2016 Mar 28	90	8	4133-49	26865719	http://www.ncbi.nlm.nih.gov/pubmed/26865719	Asbach B 2016 J Virol	Asbach B
8		Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge	"Cox JH, Ferrari MG, Earl P, Lane JR, Jagodzinski LL, Polonis VR, Kuta EG, Boyer JD, Ratto-Kim S, Eller LA, Pham DT, Hart L, Montefiori D, Ferrari G, Parrish S, Weiner DB, Moss B, Kim JH, Birx D, VanCott TC"	Vaccine	2012 Feb 27	30	10	1830-40	22234262	http://www.ncbi.nlm.nih.gov/pubmed/22234262	Cox JH 2012 Vaccine	Cox JH
9		Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization	"Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D; NISC Comparative Sequencing Program, Nason M, Valiante NM, Malyala P, De Gregorio E, Barnett SW, Singh M, O'Hagan DT, Koup RA, Mascola JR, Martin MA, Kepler TB, Douek DC, Shapiro L, Seder RA"	Nat Commun	2015 Apr 10	6		6565	25858157	http://www.ncbi.nlm.nih.gov/pubmed/25858157	Francica JR 2015 Nat Commun	Francica JR
10		Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses	"Zurawski G, Shen X, Zurawski S, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Klucar P, Wang Z, Foulds KE, Kao SF, Yu X, Sato A, Yates NL, LaBranche C, Stanfield-Oakley S, Kibler K, Jacobs B, Salazar A, Self S, Fulp W, Gottardo R, Galmin L, Weiss D, Cristillo A, Pantaleo G, Levy Y"	J Virol	2017 May 1	91	9		28202751	http://www.ncbi.nlm.nih.gov/pubmed/28202751	Zurawski G 2017 J Virol	Zurawski G
11		A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses	"Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma BJ, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF."	Virology	2006 Sep 30	353	2	268-282	17039602	https://www.ncbi.nlm.nih.gov/pubmed/17039602	Liao HX 2006 Virology	Liao HX
12		Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer	"Nkolola JP, Bricault C, Cheung A, Shields J, Perry J, Kovacs JM, Giorgi E, van Winsen M, Apetri A, Brinkman-van der Linden CM, Chen B, Korber B, Seaman MS, Barouch DH"	J Virol	2014 Sep	88	17	9538-9552	24965452	https://www.ncbi.nlm.nih.gov/pubmed/24965452	Nkolola JP 2014 J Virol	Nkolola JP
13		Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime/boost combination with Env protein in non-human primates.	"García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M"	J Virol	2015 Aug	89	16	8525-39	26041302	https://www.ncbi.nlm.nih.gov/pubmed/26041302	Garc�_a-Arriaza J 2015 J Virol	Garc�_a-Arriaza J
14		Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition	"Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, Keele BF, Shen X, Tomaras GD, Billings E, Rao M, Chung AW, Dowell KG, Bailey-Kellogg C, Brown EP, Ackerman ME, Vargas-Inchaustegui DA, Whitney S, Doster MN, Binello N, Pegu P, Montefiori DC, Foulds K, Quinn DS, Donaldson M, Liang F, Lor̩ K, Roederer M, Koup RA, McDermott A, Ma ZM, Miller CJ, Phan TB, Forthal DN, Blackburn M, Caccuri F, Bissa M, Ferrari G, Kalyanaraman V, Ferrari MG, Thompson D, Robert-Guroff M, Ratto-Kim S, Kim JH, Michael NL, Phogat S, Barnett SW, Tartaglia J, Venzon D, Stablein DM, Alter G, Sekaly RP, Franchini G"	Nat Med	2016 Jul	22	7	762-70	27239761	https://www.ncbi.nlm.nih.gov/pubmed/27239761#	Vaccari M 2016 Nat Med	Vaccari M
15		"Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study"	"Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Sțhr W, McCormack S, Shattock RJ."	PLoS One	2016 May 9	11	5		27159166	https://www.ncbi.nlm.nih.gov/pubmed/27159166	Cosgrove CA 2016 PLoS One	Cosgrove CA
16		Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques	"Zurawski G, Zurawski S, Flamar AL, Richert L, Wagner R, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Bonnabau H, Klucar P, Wang Z, Foulds KE, Kao SF, Yates NL, LaBranche C, Jacobs BL, Kibler K, Asbach B, Kliche A, Salazar A, Reed S, Self S, Gottardo R, Galmin L, Weiss D, Cristillo A, Thiebaut R, Pantaleo G, Levy Y"	PLoS One	2016 Apr 14	11	4		27077384	https://www.ncbi.nlm.nih.gov/pubmed/27077384	Zurawski G 2016 PLoS One	Zurawski G
17		Antibody 10-1074 suppresses viremia in HIV-1-infected individuals	"Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY, Learn GH, Cohen YZ, Lehmann C, Gillor D, Shimeliovich I, Unson-OBrien C, Weiland D, Robles A, K�_mmerle T, Wyen C, Levin R, Witmer-Pack M, Eren K, Ignacio C, Kiss S, West AP Jr, Mouquet H, Zingman BS, Gulick RM, Keler T, Bjorkman PJ, Seaman MS, Hahn BH, F�_tkenheuer G, Schlesinger SJ, Nussenzweig MC, Klein F"	Nat Med	2017 Feb	23	2	185-191	28092665	https://www.ncbi.nlm.nih.gov/pubmed/28092665	Caskey M 2017 Nat Med	Caskey M
77		Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV	"Paul M, Reljic R, Klein K, Drake PMW, van Dolleweerd C, Pabst M, Windwarder M, Arcalis E, Stoger E, Altmann F, Cosgrove C, Bartolf A, Baden S, Ma JKC"	mAbs	2014 Nov	6	6	1585-1597	25484063	https://www.ncbi.nlm.nih.gov/pubmed/25484063	Paul M 2014 mAbs	Paul M
78		"Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco."	"Teh AY, Maresch D, Klein K, Ma JK"	Plant Biotechnol J	2014 Apr	12	3	300-311	24256218	https://www.ncbi.nlm.nih.gov/pubmed/24256218	Teh AY 2014 Plant Biotechnol J	Teh AY
79		Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine	"Hammer SC, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB"	N Engl J Med	2013 Nov 28	369	22	2083-2092	24099601	https://www.ncbi.nlm.nih.gov/pubmed/24099601	Hammer SC 2013 N Engl J Med	Hammer SC
80	Abstract 863 characters: hDJoxyG11NJqUgDFg2qA, gif7hK7hg0 f1qt9BvGzrvdMXxCiCrM. x1hCLq8AdopPkzsuWPTZ rhSBFSgRVe X9gf4WZWEs kG0rqeetP1. Sj5n6U9nQz RMtx EiJaG1 kWHPOCkoKd ysFBFRe696 3WLrfeRKS5 yZLTIG0O8mzniwi8CI0d T6GhTW8Ed1 VrH2GJEau9 EAmrZd3Cmt FSzxwT3JcS F5D7X6K5Rb F3Rp0PUgWF QsyPgn bEci GSSIHmqWMz 2caxBEHKF7 YcjKXJFT8n hqh90Ulh3T G3pundG62H te1Crk zvKe NgfH36cjlP LMqqU9JIUY goaYn3MqZH 7a09KB9saR RfDFf1l5mv hDJ oxyG11NJqUgDFg2qA gif7hK7hg0 f1qt9BvGzrvdMXxCiCrM. x1hCLq8AdopPkzsuWPTZ rhSBFSgRVe X9g f4WZWEs kG0rqeetP1-Sj5n6U9nQz RMtx EiJaG1 kWHPOCkoKd ysFBFRe696 3WL rfeRKS5 yZLTIG0O8mzniwi8CI0d T6GhTW8Ed1 VrH2GJEau9 EAmrZd3C@mt FSz xwT3JcS F5D7X6K5Rb F3Rp0PUgWF ~QsyPgn bEci GSSIHmqWMz 2caxBEHKF7YcjKXJFT %55 8n hqh90Ulh3T G3pundG62H te1Crk zvKe NgfH36cjlP LMqqU9 JIUY *goaYn3 MqZH 7a09KB9saR RfD! (Ff1l5mvBP#I3dC2yAF4SebHoP8gFq9B5OHT) 3Z6BtbjAadN PUO169w@ jXfUcf0 +jcDF9p0 =wm9KJ4Z	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial	"Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD"	J Infect Dis	2018 Mar 28	217	8	1280-1288	29325070	https://www.ncbi.nlm.nih.gov/pubmed/29325070	Fong Y 2018 J Infect Dis	Fong Y
81		Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial	"Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ"	J Infect Dis	2017 May 1	215	9	1376-1385	28199679	https://www.ncbi.nlm.nih.gov/pubmed/28199679	Janes HE 2017 J Infect Dis	Janes HE
82		"Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV-1MN gp120, HIV-1SF2 Recombinant gp120, or Both Vaccines in Seronegative Adults"	"Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Paoletti E, and the NIAID AIDS Vaccine Evaluation Group"	J Infect Dis	1998	177	5	1230-1246	9593008	http://www.ncbi.nlm.nih.gov/pubmed/9593008	Clements-Mann ML 1998 J Infect Dis	Clements-Mann ML
83		Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers	"Belshe RB, Gorse GJ, Mulligan MJ, Evans T, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ, The NIAID AIDS Vaccine Evaluation Group"	AIDS	1998 Dec 24	12	18	2407-2415	9875578	http://www.ncbi.nlm.nih.gov/pubmed/9875578	Belshe RB 1998 AIDS	Belshe RB
84		HIV-1MN  recombinant gp160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN  recombinant gp120 vaccine	"Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB, NIAID AIDS Vaccine Evaluation Group"	AIDS Res Hum Retroviruses	1999	15	2	115-132	10029244	http://www.ncbi.nlm.nih.gov/pubmed/10029244	Gorse GJ 1999 AIDS Res Hum Retroviruses	Gorse GJ
85		A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers	"Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori D, Gorse GJ, Graham BS, McElrath MJ, Clements-Man ML, Mulligan MJ, Fast PE,  Walker MC, Excler JL, Duliege AM, Tartaglia J, NIAID AIDS Vaccine Evaluation Group"	J Infect Dis	1999	180	2	290-298	10395842	http://www.ncbi.nlm.nih.gov/pubmed/10395842	Evans TG 1999 J Infect Dis	Evans TG
86		Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women	"Wright PF, Lambert JS, Gorse GJ, Hsieh RH, McElrath MJ, Weinhold K, Wara DW, Anderson EL, Keefer MC, Jackson S, Wagner LJ, Francis DP, Fast PE, McNamara J, AIDS Vaccine Evaluation Group"	J Infect Dis	1999	180	4	1080-1088	10479134	http://www.ncbi.nlm.nih.gov/pubmed/10479134	Wright PF 1999 J Infect Dis	Wright PF
87		"A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection"	"McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P"	AIDS Res Hum Retroviruses	2000 Jun 10	16	9	907-919	10875616	http://www.ncbi.nlm.nih.gov/pubmed/10875616	McElrath MJ 2000 AIDS Res Hum Retroviruses	McElrath MJ
88		QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans	"Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D; NIAID AIDS Vaccine Evaluation Group"	Vaccine	2001 Feb 28	19	15-16	2080-2091	11228380	http://www.ncbi.nlm.nih.gov/pubmed/11228380	Evans TG 2001 Vaccine	Evans TG
89		Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study	"Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, Judson FN, McKirnan D, Sheon A, Self S, Buchbinder SP"	Am J Epidemiol	2001 Apr 1	153	7	619-627	11282787	http://www.ncbi.nlm.nih.gov/pubmed/11282787	Seage GR 3rd 2001 Am J Epidemiol	Seage GR 3rd
90		A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects 	"Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W"	Vaccine	2001 Apr 30	19	23-24	3033-3042	11311997	http://www.ncbi.nlm.nih.gov/pubmed/11311997	Lambert JS 2001 Vaccine	Lambert JS
91		Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers	"Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET)"	J Infect Dis	2001 May 1	183	9	1343-52	11294665	http://www.ncbi.nlm.nih.gov/pubmed/11294665	Belshe RB 2001 J Infect Dis	Belshe RB
92		Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A	"Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P; AIDS Vaccine Evaluation Group"	J Acquir Immune Defic Syndr	2002 Mar 1	29	3	254-261	11873074	http://www.ncbi.nlm.nih.gov/pubmed/11873074	Gupta K 2002 J Acquir Immune Defic Syndr	Gupta K
93		Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein	" Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group"	J Infect Dis	2004 Apr 1	189	7	1221-1231	15031791	http://www.ncbi.nlm.nih.gov/pubmed/15031791	 Wright PF 2004 J Infect Dis	 Wright PF
94		"High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects"	"Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L; NIAID HIV Vaccine Trials Network"	J Infect Dis	2005 Oct 1	192	7	1249-1259	16136469	http://www.ncbi.nlm.nih.gov/pubmed/16136469	Goepfert PA 2005 J Infect Dis	Goepfert PA
95		Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults	"Mulligan MJ, Russell ND, Celum C, Kahn J, Noonan E, Montefiori DC, Ferrari G, Weinhold KJ, Smith JM, Amara RR, Robinson HL; NIH/NIAID/DAIDS HIV Vaccine Trials Network"	AIDS Res Hum Retroviruses	2006 Jul	22	7	678-683	16831092	http://www.ncbi.nlm.nih.gov/pubmed/16831092	Mulligan MJ 2006 AIDS Res Hum Retroviruses	Mulligan MJ
96		Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection	"Horton H, Havenar-Daughton C, Lee D, Moore E, Cao J, McNevin J, Andrus T, Zhu H, Rubin A, Zhu T, Celum C, McElrath MJ"	J Virol	2006 Oct	80	19	9779-9788	16973582	http://www.ncbi.nlm.nih.gov/pubmed/16973582	Horton H 2006 J Virol	Horton H
97		Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers	"Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepapeliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T; NIAID HIV Vaccine Trials Network"	Vaccine	2007 Jan 5	25	3	510-8	17049679	http://www.ncbi.nlm.nih.gov/pubmed/17049679	Goepfert PA 2007 Vaccine	Goepfert PA
98		Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial	"Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network"	J Acquir Immune Defic Syndr	2007 Feb 1	44	2	203-12	17106277	http://www.ncbi.nlm.nih.gov/pubmed/17106277	Russell ND 2007 J Acquir Immune Defic Syndr	Russell ND
99		Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120	"Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network"	J Acquir Immune Defic Syndr	2007 Oct 1	46	2	222-30	17693888	http://www.ncbi.nlm.nih.gov/pubmed/17693888	Cleghorn F 2007 J Acquir Immune Defic Syndr	Cleghorn F
100		"Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults"	"Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND; HIV Vaccine Trials Network"	Vaccine	2008 Jan 10	26	2	215-23	18055072	http://www.ncbi.nlm.nih.gov/pubmed/18055072	Gorse GJ 2008 Vaccine	Gorse GJ
101		The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials	"Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C; 903 Protocol Team"	J Acquir Immune Defic Syndr	2008 May 1	48	1	82-9	18391750	http://www.ncbi.nlm.nih.gov/pubmed/18391750	Djomand G 2008 J Acquir Immune Defic Syndr	Djomand G
102		" Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial"	"Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team"	 Lancet	2008 Nov 29	372	9653	1881-93	19012954	http://www.ncbi.nlm.nih.gov/pubmed/19012954	Buchbinder SP 2008  Lancet	Buchbinder SP
103		 Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial	"Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; NIAID HIV Vaccine Trials Network"	Vaccine	2009 Jan 7	27	2	243-9	18996425	http://www.ncbi.nlm.nih.gov/pubmed/18996425	Spearman P 2009 Vaccine	Spearman P
104		A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults	"Jin X, Newman MJ, De-Rosa S, Cooper C, Thomas E, Keefer M, Fuchs J, Blattner W, Livingston BD, McKinney DM, Noonan E, Decamp A, Defawe OD, Wecker M; NIAID HIV Vaccine Trials Network"	Vaccine	2009 Nov 23	27	50	7080-6	19786145	http://www.ncbi.nlm.nih.gov/pubmed/19786145	Jin X 2009 Vaccine	Jin X
105		"Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity"	"Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF; the AIDS Vaccine Evaluation Group"	PLoS One	2010 Aug 10	5	8	e11995	20706632	http://www.ncbi.nlm.nih.gov/pubmed/20706632	Graham BS 2010 PLoS One	Graham BS
106		Safety and Immunogenicity of the MRKAd5 gag HIV-1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults	"Nicholson O, DiCandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM,  HVTN 050 Study eam"	AIDS Res Hum Retroviruses	2010 Nov 23	27	5	 557���567	20854108	http://www.ncbi.nlm.nih.gov/pubmed/20854108	Nicholson O 2010 AIDS Res Hum Retroviruses	Nicholson O
107		Safety and immunogenicity of a single-dose recombinant adenovirus type 5 multiclade HIV-1 vaccine in persons without previous vector immunity: A randomized clinical trial (HVTN study 054)	"Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, DeRosa SC, McElrath MJ"	PLoS ONE	2010 Oct 27	5	10	e13579	21048953	http://www.ncbi.nlm.nih.gov/pubmed/21048953	Peiperl L 2010 PLoS ONE	Peiperl L
108		A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects	"Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; the NIAID HIV Vaccine Trials Network"	Vaccine	2011 Feb 24	29	10	1948-1958	3043112	http://www.ncbi.nlm.nih.gov/pubmed/21216311	Keefer MC 2011 Vaccine	Keefer MC
109		Phase 1 safety and immunogenicity testing of DNA and recombinant Modified Vaccinia Ankara vaccines expressing HIV-1 virus-like particles	"Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, Derosa SC, Defawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; the National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network"	J Infect Dis	2011 Mar	203	5	610-9	3072720	http://www.ncbi.nlm.nih.gov/pubmed/21282192	Goepfert PA 2011 J Infect Dis	Goepfert PA
110		"A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers"	"Spearman P, Lally MA, Elizaga M, Montefiori D, Tomaras GD, McElrath MJ, Hural J, De Rosa SC, Sato A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ; HIV Vaccine Trials Network of NIAID"	J Infect Dis	2011 Apr	203	8	1165-1173	3068023	http://www.ncbi.nlm.nih.gov/pubmed/21451004	Spearman P 2011 J Infect Dis	Spearman P
111		"Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study"	"Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; on behalf of the HVTN 503/Phambili study team"	Lancet Infect Dis	2011 Jul	11	7	507-515	3417349	http://www.ncbi.nlm.nih.gov/pubmed/21570355	Gray GE 2011 Lancet Infect Dis	Gray GE
112		A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults	"Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network"	PLoS One	2011	6	8	e21225	3152265	http://www.ncbi.nlm.nih.gov/pubmed/21857901	Churchyard GJ 2011 PLoS One	Churchyard GJ
113		Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: A randomized clinical trial	"Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC, McElrath MJ, Saavedra L, Lau CY, Graham BS, The NIAID HIV Vaccine Trials Network"	PLoS ONE	2011	6	9	e24517	3171485	http://www.ncbi.nlm.nih.gov/pubmed/21931737	Koblin BA 2011 PLoS ONE	Koblin BA
114		HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable	"De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ; the National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network"	J Immunol	2011 Sep 15	187	6	3391-3401	3180898	http://www.ncbi.nlm.nih.gov/pubmed/21844392	De Rosa SC 2011 J Immunol	De Rosa SC
115		Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects	"Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R; the NIAID HIV Vaccine Trials Network 044 Study Team"	J Infect Dis	2011 Nov 15	204	10	1541-9	3222108	http://www.ncbi.nlm.nih.gov/pubmed/21940420	Baden LR 2011 J Infect Dis	Baden LR
116		"Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults"	"Kalams SA , Parker S , Jin X , Elizaga M , Metch B, Wang, M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR, the NIAID HIV Vaccine Trials Network"	PLoS ONE	2012	7	1	e29231	3252307	http://www.ncbi.nlm.nih.gov/pubmed/22242162	Kalams SA  2012 PLoS ONE	Kalams SA
117		"DNA and Modified Vaccinia Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes are safe but weakly immunogenic in HIV-1-uninfected, Vaccinia-naive adults"	"Gorse GJ, Newman MJ, deCamp A, Hay CM, DeRosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Chavami FL, the NIAID HIV Vaccine Trials Network"	Clin Vaccine Immunol	2012 May	19	5	649-58	22398243	http://www.ncbi.nlm.nih.gov/pubmed/22398243	Gorse GJ 2012 Clin Vaccine Immunol	Gorse GJ
118		Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step study)	"Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; for the Step / HVTN 504 Study Team"	J Infect Dis	2012  Jul 15	206	2	258-66	22561365	http://www.ncbi.nlm.nih.gov/pubmed/22561365	Duerr A 2012 J Infect Dis	Duerr A
119		Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101) in healthy HIV-1 uninfected adults	"Wecker M, Gilbert P, Russell N, Hural J, Torres K, Allen M, Chulay J, Abdool Karim SS, Burke D, and the HVTN 040/059 Protocol Team"	Clin Vaccine Immunol	2012 Oct	19	10	1651-60	3485893	http://www.ncbi.nlm.nih.gov/pubmed/22914365	Wecker M 2012 Clin Vaccine Immunol	Wecker M
120		Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials	"Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G, Koblin B"	AIDS Behav	2013 Feb	17	2	760-72	23090677	http://www.ncbi.nlm.nih.gov/pubmed/23090677	Metch B 2013 AIDS Behav	Metch B
121		Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: Longitudinal results of HVTN 906	"Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, Frank I; on behalf of the HVTN 906 study team"	J Acquir Immune Defic Syndr	2013 Jun 1	63	2	239-44	23446497	http://www.ncbi.nlm.nih.gov/pubmed/23446497	Koblin BA 2013 J Acquir Immune Defic Syndr	Koblin BA
122		Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery	"Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; for the NIAID HIV Vaccine Trials Network"	J Infect Dis	2013  Sep 1	208	5	818-29	23840043	http://www.ncbi.nlm.nih.gov/pubmed/23840043	Kalams SA 2013 J Infect Dis	Kalams SA
123		Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles	"Goepfert PA, Elizaga ML, Seaton KE, Tomaras GD, Montefiori DC, Sato A, Hural J, Derosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder S, Hammer S, Koblin B, Pensiero M, Butler C, Moss B, Robinson HL; the HVTN 205 Study Group; the National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network"	J Infect Dis	2014 Jul 1	10	1	99-110	24403557	http://www.ncbi.nlm.nih.gov/pubmed/24403557	Goepfert PA 2014 J Infect Dis	Goepfert PA
124		"Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants"	"Frey SE, Peiperl L, McElrath MJ, Goepfert PA, Keefer MC, Baden LR, Lally MA, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Mayer K, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L"	Clin Vaccine Immunol	2014 Nov	21	11	1589-99	25253665	http://www.ncbi.nlm.nih.gov/pubmed/25253665	Frey SE 2014 Clin Vaccine Immunol	Frey SE
125		HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial	"Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, Shen X, Allen MA, Ding S, Hural J, Liao HX, Haynes BF, Graham BS, Gilbert PB, McElrath MJ, Montefiori DC, Tomaras GD, Pantaleo G, Frahm N"	J Clin Invest	2014  Nov 3	124	11	4843-56	25271627	http://www.ncbi.nlm.nih.gov/pubmed/25271627	Bart PA 2014 J Clin Invest	Bart PA
126		Safety and immunogenicity of a recombinant adenovirus serotype 35-vectored HIV-1 vaccine in adenovirus serotype 5 seronegative and seropositive individuals	"Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert P, Kochar N, DeRosa S, Tomaras G, Wagner T, Baden L, Koblin B, Rouphael N, Kalams S, Keefer M, Goepfert P, Sobieszczyk M, Mayer K, Swann E, Liao H-X, Haynes B, Graham B, and McElrath MJ for the NIAID HIV Vaccine Trials Network"	J AIDS Clin Res	2015 May 23	6	461		26587311	http://www.ncbi.nlm.nih.gov/pubmed/26587311	Fuchs JD 2015 J AIDS Clin Res	Fuchs JD
127		First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus (rVSV) HIV-1 gag vaccine (HVTN 090)	"Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams S, Tomaras G, Sheets R, Pensiero M, Tremblay M, Higgins T, Latham T, Egan M, Clarke D, Eldridge J, for the HVTN 090 Study Group and the NIAID HIV Vaccine Trials Network"	Open Forum Infect Dis	2015 Jun 5	2	3	ofv082	26199949	http://www.ncbi.nlm.nih.gov/pubmed/26199949	Fuchs JD 2015 Open Forum Infect Dis	Fuchs JD
128		Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907	"Deschamps MM, Metch B, Morgan C, Zorilla CD, Donastorg Y, Swann E, Taina D, Patrice J, Pape JW on behalf of the HVTN 907 Study Team"	J Acquir Immune Defic Syndr	2016 Jan 1	71	1	70-7	26761272	http://www.ncbi.nlm.nih.gov/pubmed/26761272	Deschamps MM 2016 J Acquir Immune Defic Syndr	Deschamps MM
129		Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083)	"Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Hertz T, Self SG, Friedrich D, Frahm N, Liao H-X, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X, the HVTN 083 Study Group, and the NIAID HIV Vaccine Trials Network"	J Infect Dis	2016 Feb 15	213	4	541-50	26475930	http://www.ncbi.nlm.nih.gov/pubmed/26475930	Walsh SR 2016 J Infect Dis	Walsh SR
130		Subtype C gp140 vaccine boosts immune responses primed by SAAVI DNA-C2 and MVA-C HIV vaccine after more than a two year gap (HVTN 073E/SAAVI 102)	"Gray GE, Mayer KH, Elizaga ML, Bekker LG, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N, Tomaras GD, Tucker T, Barnett SW, Mkhize NN, Shen X, Downing K, Williamson C, Pensiero M, Corey L, Williamson AL; NIAID-funded HIV Vaccine Trials Network"	Clin Vaccine Immunol	2016 Jun 6	23	6	496-506	27098021	http://www.ncbi.nlm.nih.gov/pubmed/27098021	Gray GE 2016 Clin Vaccine Immunol	Gray GE
131		Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection	"Lama JR, Karuna ST, Grant SP, Swann EM, Ganoza C, Segura P, Montano SM, Lacherre M, De Rosa SC, Buchbinder S, Sanchez J, McElrath MJ, Lemos MP, for the HVTN 914 Study Team"	PLoS One	2016 Aug 18	11	8	e0160487	27536938	http://www.ncbi.nlm.nih.gov/pubmed/27536938	Lama JR 2016 PLoS One	Lama JR
132		Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants	"Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L"	PLoS One	2016 Sep 1	11	9	e0161753	27583368	http://www.ncbi.nlm.nih.gov/pubmed/27583368	Churchyard G 2016 PLoS One	Churchyard G
133		Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults	"Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD, on behalf of the HVTN 094 Study Group"	PLoS One	2017 Jul 20	12	7	e0179597	28727817	https://www.ncbi.nlm.nih.gov/pubmed/28727817	Buchbinder SP 2017 PLoS One	Buchbinder SP
134		DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8+ T-cell responses by IL-12 pDNA	"Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network"	Clin Vaccine Immunol	2017 Nov 6	24	11		28931520	https://www.ncbi.nlm.nih.gov/pubmed/28931520	Li SS 2017 Clin Vaccine Immunol	Li SS
135		"Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial"	"Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, Bailer RT, Ferrari G, Jensen R, Hural J, Graham BS, Mascola JR, Corey L, Montefiori DC; HVTN 104 Protocol Team; and the NIAID HIV Vaccine Trials Network"	PLoS Med	2017 Nov 14	14	11	e1002435	29136037	https://www.ncbi.nlm.nih.gov/pubmed/29136037	Mayer KH 2017 PLoS Med	Mayer KH
136	Abstract 214 characters: 15V1tGLffV Z0xdH6A1g2? lUQmGJstMw 7<9 ylGPHBOpQu/6IrVti1P6t U7rAvLDqga vdLqgWs74G WDa48nJk4T szbocQyaxt BhEWrQAqR5 1e_&`xJR+ &a!=nuioj (ra@Zp)QY !L*Uxce6= gB3)Vxj$! eO9(P9E`+ f~UHh#E33 HZ_`0KipF 0(mWj7t*u pphCI$@MR	A phase 1/2 HIV-1 vaccine trial of a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 vaccine regimen in low risk HIV uninfected South African adults	"Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ on behalf of the HVTN 100 Protocol Team"	Lancet HIV	2018 Jul	5	7	e366-e378	29898870	https://www.ncbi.nlm.nih.gov/pubmed/29898870	Bekker LG 2018 Lancet HIV	Bekker LG
137		Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity	"Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, Schwartz DH"	J Infect Dis	2000	181		897-903	10720510	http://www.ncbi.nlm.nih.gov/pubmed/10720510	Castillo RC 2000 J Infect Dis	Castillo RC
138		False positivity of enzyme-linked immunosorbent assay for measurement of secretory IgA antibodies directed at HIV type 1 antigens	"Jackson S, Prince S, Kulhavy R, Mestecky J"	AIDS Res Hum Retroviruses	2000	16		595-602	10777150	http://www.ncbi.nlm.nih.gov/pubmed/10777150	Jackson S 2000 AIDS Res Hum Retroviruses	Jackson S
139		"Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil - Projeto Praco Onze Study Group"	"Schechter M, do Lago RF, de Melo MF, Sheppard HW, Guimaṛes NC, Moreira RI, Faulhaber JC, Batista S, Harrison LH"	J Acquir Immune Defic Syndr	2000 Jun 1	24	2	175-7	10935694	http://www.ncbi.nlm.nih.gov/pubmed/10935694	Schechter M 2000 J Acquir Immune Defic Syndr	Schechter M
140		Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine	"Sabbaj S, Mulligan MJ, Hsieh RH, Belshe RB, McGhee JR"	AIDS	2000 Jul 7	14	10	1365-74	10930151	http://www.ncbi.nlm.nih.gov/pubmed/10930151	Sabbaj S 2000 AIDS	Sabbaj S
141		 Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials	"Koblin BA, Holte S, Lenderking B, Heagerty P, The HIVNET Vaccine Preparedness Study Protocol Team"	J Acquir Immune Defic Syndr	2000 Aug 15	24	5	451-7	11035616	http://www.ncbi.nlm.nih.gov/pubmed/11035616	Koblin BA 2000 J Acquir Immune Defic Syndr	Koblin BA
142		Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City	"Brown-Peterside P, Chiasson MA, Ren L, Koblin BA"	Journal of Urban Health	2000	77		425-437	10976615	http://www.ncbi.nlm.nih.gov/pubmed/10976615	Brown-Peterside P 2000 Journal of Urban Health	Brown-Peterside P
143		Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by gp160 protein boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1	"Bures R, Gaitan A, Zhu T, Graziosi C, McGrath KM, Tartaglia J, Caudrelier P, El Habib R, Klein M, Lazzarin A, Stablein DM, Deers M, Corey L, Greenberg ML, Schwartz DH, Montefiori DC"	AIDS Research and Human Retroviruses	2000	16		2019-35	11153085	http://www.ncbi.nlm.nih.gov/pubmed/11153085	Bures R 2000 AIDS Research and Human Retroviruses	Bures R
144		Trial-related discrimination in HIV vaccine clinical trials	"Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S"	AIDS Research and Human Retroviruses	2001	17		667-674	11429107	http://www.ncbi.nlm.nih.gov/pubmed/11429107	Allen M 2001 AIDS Research and Human Retroviruses	Allen M
145		Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120	"Gorse GJ, Patel GB, Mandava MD, Arbuckle JA, Doyle TM, Belshe RB; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group"	Vaccine	2001	19		1806-1819	11166906	http://www.ncbi.nlm.nih.gov/pubmed/11166906	Gorse GJ 2001 Vaccine	Gorse GJ
146		Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production	"Evans TG, Kallas EG, Campbell M, Andrews J, Schwartz D, Keefer M, Caudrelier P"	Immunol Lett	2001	77	1	15-Jul	11348664	http://www.ncbi.nlm.nih.gov/pubmed/11348664	Evans TG 2001 Immunol Lett	Evans TG
147		Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production	"Worku S, Gorse GJ, Belshe RB, Hoft DF"	J Infect Dis	2001 Sep 1	184	5	525-32	11474428	http://www.ncbi.nlm.nih.gov/pubmed/11474428	Worku S 2001 J Infect Dis	Worku S
148		CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition	"Ferrari G, Neal W, Jones A, Olender N, Ottinger J, Ha R, McElrath MJ, Goepfert P, Weinhold KJ"	Immunol Lett	2001 Nov 1	79	2-Jan	37-45	11595288	http://www.ncbi.nlm.nih.gov/pubmed/11595288	Ferrari G 2001 Immunol Lett	Ferrari G
149		Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity	"Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ"	J Infect Dis	2003 Jan 15	187	22	226-42	12552447	http://www.ncbi.nlm.nih.gov/pubmed/12552447	Russell ND 2003 J Infect Dis	Russell ND
150		Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials	Hudgens MG	Stat Med	2003 Feb 15	22	3	463-79	12529875	http://www.ncbi.nlm.nih.gov/pubmed/12529875	Hudgens MG 2003 Stat Med	Hudgens MG
151		Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients	"Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, Allen M, McDougal JS"	J Infect Dis	2003 Mar 15	187	6	879-86	12660933	http://www.ncbi.nlm.nih.gov/pubmed/12660933	Ackers ML 2003 J Infect Dis	Ackers ML
152		Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials	"Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network"	Vaccine	2003 Jun 20	21	21-22	2933-47	12798637	http://www.ncbi.nlm.nih.gov/pubmed/12798637	Gilbert PB 2003 Vaccine	Gilbert PB
153		HIV-1 Vaccination Administered Intramuscularly Can Induce Both Systemic and Mucosal T Cell Immunity in HIV-1 Uninfected Individuals	"Musey L, Ding Y, Elizaga M, Ha R, Celum C, McElrath MJ"	J Immunol	2003 Jul 15	171	2	1094-101	12847284	http://www.ncbi.nlm.nih.gov/pubmed/12847284	Musey L 2003 J Immunol	Musey L
154		Safety Profile of recombinant canarypox HIV Vaccines	"de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC"	Vaccine	2004 Jan 26	22	6-May	704-13	14741163	http://www.ncbi.nlm.nih.gov/pubmed/14741163	de Bruyn G 2004 Vaccine	de Bruyn G
155		Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials	"Hudgens MG, Self SG, Chiu YL, Russell ND, Horton H, McElrath MJ"	J Immunol Methods	2004 May	288	2-Jan	19-34	15183082	http://www.ncbi.nlm.nih.gov/pubmed/15183082	Hudgens MG 2004 J Immunol Methods	Hudgens MG
156		"Absence of Immunodominant Anti-Gag p17 (SL9) Responses Among Gag CTL-positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele"	"Ferrari G, Neal W, Ottinger J, Jones AM, Edwards BH, Goepfert P, Betts MR, Koup RA, Buchbinder S, McElrath MJ, Tartaglia J, Weinhold KJ"	J Immunol	2004 Aug 1	173	3	2126-33	15265949	http://www.ncbi.nlm.nih.gov/pubmed/15265949	Ferrari G 2004 J Immunol	Ferrari G
157		Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160	"Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL"	J Infect Dis	2004 Sep 1	190	5	903-7	15295694	http://www.ncbi.nlm.nih.gov/pubmed/15295694	Lee D 2004 J Infect Dis	Lee D
158		"Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells"	"Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, Lee D, Deers M, Hudgens M, Weinhold K, McElrath MJ"	J Infect Dis	2004 Nov 1	190	9	1692-6	15478077	http://www.ncbi.nlm.nih.gov/pubmed/15478077	Horton H 2004 J Infect Dis	Horton H
159		Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines	"Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network"	J Infect Dis	2004 Dec 1	190	11	1962-9	15529261	http://www.ncbi.nlm.nih.gov/pubmed/15529261	Montefiori DC 2004 J Infect Dis	Montefiori DC
160		Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection	"Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM, Ambrozak DR, Tomaras G, Roederer M, Kilby JM, Tartaglia J, Belshe R, Gao F, Douek DC, Weinhold KJ, Koup RA, Goepfert P, Ferrari G"	Proc Natl Acad Sci U S A	2005 Mar 22	102	12	4512-7	15753288	http://www.ncbi.nlm.nih.gov/pubmed/15753288	Betts MR 2005 Proc Natl Acad Sci U S A	Betts MR
161		Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa	"Gray CM, Williamson C, Bredell H, Puren A, Xia X, Filter R, Zijenah L, Cao H, Morris L, Vardas E, Colvin M, Gray G, McIntyre J, Musonda R, Allen S, Katzenstein D, Mbizo M, Kumwenda N, Taha T, Karim SA, Flores J, Sheppard HW"	AIDS Res Hum Retroviruses	2005 Apr	21	4	285-91	15943570	http://www.ncbi.nlm.nih.gov/pubmed/15943570	Gray CM 2005 AIDS Res Hum Retroviruses	Gray CM
162		Participant retention in clinical trials of candidate HIV vaccines	"de Bruyn G, Hudgens MG, Sullivan PS, Duerr AC"	J Acquir Immune Defic Syndr	2005 Aug 1	39	4	499-501	16010176	http://www.ncbi.nlm.nih.gov/pubmed/16010176	de Bruyn G 2005 J Acquir Immune Defic Syndr	de Bruyn G
163		Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies	"Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC"	J Virol	2005 Aug	79	16	10108-25	16051804	http://www.ncbi.nlm.nih.gov/pubmed/16051804	Li M 2005 J Virol	Li M
164		"Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002"	"Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS"	Public Health Rep	2005 Sep-Oct	120	5	543-8	16224987	http://www.ncbi.nlm.nih.gov/pubmed/16224987	Djomand G 2005 Public Health Rep	Djomand G
165		Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1	"Gorse GJ, Simionescu RE, Patel GB"	Clin Vaccine Immunol	2006 Jan	13	1	26-32	16425996	http://www.ncbi.nlm.nih.gov/pubmed/16425996	Gorse GJ 2006 Clin Vaccine Immunol	Gorse GJ
166		The use of an educational video during informed consent in an HIV clinical trial in Haiti	"Joseph P, Schackman BR, Horwitz R, Nerette S, Verdier RI, Dorsainvil D, Theodore H, Ascensio M, Henrys K, Wright PF, Johnson W, Pape JW, Fitzgerald DW"	J Acquir Immune Defic Syndr	2006 Aug 15	42	5	588-91	16837867	http://www.ncbi.nlm.nih.gov/pubmed/16837867	Joseph P 2006 J Acquir Immune Defic Syndr	Joseph P
167		Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection	"Horton H, Frank I, Baydo R, Jalbert E, Penn J, Wilson S, McNevin JP, McSweyn MD, Lee D, Huang Y, De Rosa SC, McElrath MJ"	J Immunol	2006 Nov 15	177	10	7406-15	17082660	http://www.ncbi.nlm.nih.gov/pubmed/17082660	Horton H 2006 J Immunol	Horton H
168		HIV vaccine efficacy trials: towards the future of HIV prevention	"Kim D, Elizaga M, Duerr A"	Infect Dis Clin North Am	2007 Mar	21	1	201-17	17502236	http://www.ncbi.nlm.nih.gov/pubmed/17502236	Kim D 2007 Infect Dis Clin North Am	Kim D
169		HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.	"McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team"	Lancet	2008 Nov 29	372	9653	1894-905	19012957	http://www.ncbi.nlm.nih.gov/pubmed/19012957	McElrath MJ 2008 Lancet	McElrath MJ
170		HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.	"Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, Robertson MN"	Clin Infect Dis	2008 Dec 15	47	12	1593-9	18990058	http://www.ncbi.nlm.nih.gov/pubmed/18990058	Quirk EK 2008 Clin Infect Dis	Quirk EK
171		Low HIV seroincidence among female commercial sex workers: a barrier for measuring HIV vaccine efficacy.	"Djomand G, Beyrer C, Buchbinder S."	J Acquir Immune Defic Syndr	2008 Dec 15	49	5	570	19202462	http://www.ncbi.nlm.nih.gov/pubmed/19202462	Djomand G 2008 J Acquir Immune Defic Syndr	Djomand G
172		Barriers to recruit female commercial sex workers for HIV vaccine trials: the Rio de Janeiro experience.	"Barroso PF, de Souza MB, do Lago RF, Pedrosa J, Yoshida CB, Faulhaber JC, Costa MD, Schechter M."	J Acquir Immune Defic Syndr	2009 Jan 1	50	1	116-7	19092453	http://www.ncbi.nlm.nih.gov/pubmed/19092453	Barroso PF 2009 J Acquir Immune Defic Syndr	Barroso PF
173		"In ""Step"" with HIV Vaccines? A Content Analysis of Local Recruitment Campaigns for an International HIV Vaccine Study."	"Frew PM, Macias W, Chan K, Harding AC."	J Health Mass Commun	2009	1	1	Nov-39	19609373	http://www.ncbi.nlm.nih.gov/pubmed/19609373	Frew PM 2009 J Health Mass Commun	Frew PM
174		Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials.	"Gilbert PB, Sato A, Sun X, Mehrotra DV"	Vaccine	2009 Jan 14	27	3	396-401	19022314	http://www.ncbi.nlm.nih.gov/pubmed/19022314	Gilbert PB 2009 Vaccine	Gilbert PB
175		Understanding differences in enrollment outcomes among high-risk populations recruited to a phase IIb HIV vaccine trial	"Frew PM, del Rio C, Lu L, Clifton S, Mulligan MJ."	J Acquir Immune Defic Syndr	2009 Mar 1	50	3	314-9	19194310	http://www.ncbi.nlm.nih.gov/pubmed/19194310	Frew PM 2009 J Acquir Immune Defic Syndr	Frew PM
176		Uptake of male circumcision in an HIV vaccine efficacy trial.	"de Bruyn G, Martinson NA, Nkala BD, Tshabangu N, Shilaluka G, Kublin J, Corey L, Gray GE."	J Acquir Immune Defic Syndr	2009 May 1	51	1	108-10	19390332	http://www.ncbi.nlm.nih.gov/pubmed/19390332	de Bruyn G 2009 J Acquir Immune Defic Syndr	de Bruyn G